A New Era in Recurrent LGSOC: Incorporating Approved Therapies, Biomarkers, and Clinical Strategies
Industry Supported Symposium
Activity Overview
The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to attend the A New Era in Recurrent LGSOC: Incorporating Approved Therapies, Biomarkers, and Clinical Strategies Industry Supported Symposium being held in-person at the IGCS 2025 Annual Global Meeting in Cape Town, South Africa on Thursday, November 6, 2025 from 11:55 – 13:25 GMT+2.
This symposium will explore the rapidly evolving landscape of treatment for recurrent low-grade serous ovarian cancer (LGSOC), with a focus on newly FDA-approved therapies and investigational strategies, MEC Inhibitors, CDK46 Inhibitors, hormonal treatments and other opportunities in the competitive landscape. LGSOC remains a challenging subtype due to its unique biology and resistance to conventional therapies. Faculty will examine recent clinical trial data, discuss emerging best practices for biomarker testing and sequencing, and explore practical considerations for managing side effects and ensuring patient access to innovative treatments. Through real-world cases and interactive discussion, participants will gain insights to personalize care and optimize outcomes for patients living with recurrent LGSOC.
This non-promotional symposium is organized and funded by Verastem in collaboration with The GOG Foundation, Inc.
Target Audience
Gynecologic and medical oncologists, oncology researchers, clinical trial investigators, advanced practice providers, and healthcare professionals involved in the care of patients with ovarian cancer.
Learning Objectives
Upon completion of the activities in this series, learners will be able to:
- Describe the challenges in managing recurrent low-grade serous ovarian cancer (LGSOC) and understand the clinical complexities associated with this disease.
- Summarize the most recent clinical trial data and treatment options for recurrent LGSOC, including novel and FDA-approved therapies, FDA-approved therapies and investigational strategies, MEC Inhibitors, CDK46 Inhibitors, hormonal treatments and other opportunities in the competitive landscape.
- Understand the role and importance of biomarker testing and sequencing in informing treatment decisions.
- Discuss strategies for accessing newly approved treatments and managing associated side effects in clinical practice.
- Highlight future directions for integrating precision medicine and emerging investigational strategies in the care of patients with recurrent LGSOC.
Agenda
A New Era in Recurrent LGSOC: Incorporating Approved Therapies, Biomarkers, and Clinical Strategies, an Industry Supported Symposium at the IGCS 2025 Annual Global Meeting
This session is not included in the main event CME/CPD credit.
In Person on Thursday, November 6, 2025 from 11:55 – 13:25 GMT+2 in Cape Town, South Africa
Brian Slomovitz, MD, FACOG, Mount Sinai Medical Center, Miami Beach, Florida, USA
Saketh Guntupalli, MD, University of Colorado School of Medicine, Aurora, Colorado, USA
Susana Banerjee, MBBS, MA, PhD, FRCP, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Saketh Guntupalli, MD, University of Colorado School of Medicine, Aurora, Colorado, USA
Brian Slomovitz, MD, FACOG, Mount Sinai Medical Center, Miami Beach, Florida, USA